论文部分内容阅读
用人源性ＴＰＯ（ｈｕＴＰＯ）皮下免疫ＢＡＬＢ／ｃ小鼠，取脾细胞与ＳＰ２／０实体瘤细胞融合，建立了２株稳定分泌抗ＴＰＯ单克隆抗体的杂交瘤细胞株，分别命名为１９Ｄ１２和４９Ａ５，并对其进行了初步鉴定，采用简易正辛酸法从腹水中纯化单克隆抗体。结果：细胞融合率为８２％，杂交瘤细胞染色体数目正常，分泌的抗体为ＩｇＧ，腹水抗体效价为０．６～１．２×１０－５，与ＥＰＯ、ＧＭ－ＣＳＦ无交叉反应，连续培养生物性状稳定。抗ＴＰＯ单克隆抗体杂交瘤细胞株的建立，为深入研究ＴＰＯ的生物学性质及临床应用提供了有力的工具
BALB / c mice were immunized subcutaneously with human TPO (huTPO) and spleen cells were fused with SP2 / 0 solid tumor cells. Two hybridoma cell lines stably secreting anti-TPO monoclonal antibodies were established and named as 19D12 and 49A5 , And preliminary identification of the monoclonal antibody was purified from ascites using simple octanoic acid method. Results: The cell fusion rate was 82%. The number of hybridoma cells was normal. The secreted antibody was IgG. The antibody titer of ascites was 0.6 ~ 1.2 × 10-5. There was no cross-reaction with EPO and GM-CSF, Cultivate biological stability. The establishment of anti-TPO monoclonal antibody hybridoma cell line provides a powerful tool for further study on the biological properties and clinical application of TPO